Literature DB >> 12160520

Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma.

Christoph A Meier1, Rachel Chicheportiche, Cristiana E Juge-Aubry, Magali G Dreyer, Jean-Michel Dayer.   

Abstract

Monocytes/macrophages (Mphi) play a pivotal role in the persistence of chronic inflammation and local tissue destruction in diseases such as rheumatoid arthritis and atherosclerosis. The production by Mphi of cytokines, chemokines, metalloproteinases and their inhibitors is an essential component in this process, which is tightly regulated by multiple factors. The peroxisome proliferator-activated receptors (PPARs) were shown to be involved in modulating inflammation. PPARgamma is activated by a wide variety of ligands such as fatty acids, the anti-diabetic thiazolidinediones (TZDs), and also by certain prostaglandins of which 15-deoxy-Delta(12,14)-PGJ2 (PGJ2). High concentrations of PPARgamma ligands were shown to have anti-inflammatory activities by inhibiting the secretion of interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFalpha) by stimulated monocytes. The aim of this study was to determine whether PGJ2 and TZDs would also exert an immunomodulatory action through the up-regulation of anti-inflammatory cytokines such as the IL-1 receptor antagonist (IL-1Ra). THP-1 monocytic cells were stimulated with PMA, thereby enhancing the secretion of IL-1, IL-6, TNFalpha, IL-1Ra and metalloproteinases. Addition of PGJ2 had an inhibitory effect on IL-1, IL-6 and TNFalpha secretion, while increasing IL-1Ra production. In contrast, the bona fide PPARgamma ligands (TZDs; rosiglitazone, pioglitazone and troglitazone) barely inhibited proinflammatory cytokines, but strongly enhanced the production of IL-1Ra from PMA-stimulated THP-1 cells. Unstimulated cells did not respond to TZDs in terms of IL-1Ra production, suggesting that in order to be effective, PPAR ligands depend on PMA signalling. Basal levels of PPARgamma are barely detectable in unstimulated THP-1 cells, while stimulation with PMA up-regulates its expression, suggesting that higher levels of PPARgamma expression are necessary for receptor ligand effects to occur. In conclusion, we demonstrate for the first time that TZDs may exert an anti-inflammatory activity by inducing the production of the IL-1Ra.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160520     DOI: 10.1006/cyto.2002.1945

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  23 in total

1.  Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis.

Authors:  Peter C Konturek; Artur Dembinski; Zygmunt Warzecha; Grzegorz Burnat; Piotr Ceranowicz; Eckhart G Hahn; Marcin Dembinski; Romana Tomaszewska; Stanislaw J Konturek
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

Review 2.  Transcriptional control of macrophage polarisation in type 2 diabetes.

Authors:  Karima Drareni; Jean-François Gautier; Nicolas Venteclef; Fawaz Alzaid
Journal:  Semin Immunopathol       Date:  2019-05-02       Impact factor: 9.623

Review 3.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

Authors:  Vanessa Dubois; Jérôme Eeckhoute; Philippe Lefebvre; Bart Staels
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

4.  Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor.

Authors:  Yujuan Zhang; Saloni Gupta; Alexandra Ilstad-Minnihan; Sashi Ayyangar; Arielle D Hay; Virginia Pascual; Norman T Ilowite; Claudia Macaubas; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2018-06-19       Impact factor: 3.969

5.  Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.

Authors:  Yang Yu; Bao-Jian Xue; Shun-Guang Wei; Zhi-Hua Zhang; Terry G Beltz; Fang Guo; Alan Kim Johnson; Robert B Felder
Journal:  Hypertension       Date:  2015-06-22       Impact factor: 10.190

Review 6.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 7.  The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.

Authors:  Wai San Cheang; Xiao Yu Tian; Wing Tak Wong; Yu Huang
Journal:  Br J Pharmacol       Date:  2015-01-23       Impact factor: 8.739

8.  Invariant NKT Cell Activation Induces Late Preterm Birth That Is Attenuated by Rosiglitazone.

Authors:  Derek St Louis; Roberto Romero; Olesya Plazyo; Marcia Arenas-Hernandez; Bogdan Panaitescu; Yi Xu; Tatjana Milovic; Zhonghui Xu; Gaurav Bhatti; Qing-Sheng Mi; Sascha Drewlo; Adi L Tarca; Sonia S Hassan; Nardhy Gomez-Lopez
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

9.  Copper chelation represses the vascular response to injury.

Authors:  Lazar Mandinov; Anna Mandinova; Stanimir Kyurkchiev; Dobroslav Kyurkchiev; Ivan Kehayov; Vihren Kolev; Raffaella Soldi; Cinzia Bagala; Ebo D de Muinck; Volkhard Lindner; Mark J Post; Michael Simons; Stephen Bellum; Igor Prudovsky; Thomas Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-16       Impact factor: 11.205

10.  A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.

Authors:  Hong-Liang Liang; Qin Ouyang
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.